Pattern Bioscience

• 28/04/2023
• Series C
• $28,700,000

Tackling a global health threat like antimicrobial resistance is not for the faint of heart, but the experienced and innovative team at Pattern Bioscience is on a mission to do it.

Each year, drug-resistant bacterial infections claim more than a million lives globally and cost our healthcare system billions of dollars. Traditional diagnostic methods for bacterial infections remain rooted in slow, cumbersome, decades-old technology that contributes to sub-optimal treatment and the misuse of broad-spectrum antibiotics.

The Pattern system is different. We’re developing the world’s only culture-free, rapid diagnostic technology that will reduce the time needed for pathogen identification (ID) and antibiotic susceptibility test (AST) results from days to hours. Our technology combines single-cell analysis of microorganisms with machine learning tools to deliver fast, clinically actionable information.

The result? Patients get the right treatment faster, to save lives, prevent side effects and reduce healthcare costs.

---

---